When drugs in the same controlled substance schedule differ in real-world abuse, should they be differentiated in labeling?

Drug and Alcohol Dependence

Volumn 119, Issue 1-2, 2011, Pages

  Dasgupta, Nabarun ^a,b   Henningfield, Jack E ^b   Ertischek, Michelle D ^b   Schnoll, Sidney H ^b  

^a University of North Carolina at Chapel Hill   (United States)

^b 3 Bethesda Metro Center ^*  (United States)

Author keywords

Controlled Substances Act; International treaties; Opioids; Prescription drug abuse; Risk management; Stimulants

Indexed keywords

OPIATE;

ARTICLE; DRUG DOSE REGIMEN; DRUG LABELING; MEDICAL DECISION MAKING; POSTMARKETING SURVEILLANCE; PRESCRIPTION; PRIORITY JOURNAL; PUBLIC HEALTH; RISK MANAGEMENT; SUBSTANCE ABUSE;

ANALGESICS, OPIOID; DRUG LABELING; DRUG PRESCRIPTIONS; HUMANS; OVERDOSE; PRESCRIPTION DRUGS; RISK; RISK MANAGEMENT; SUBSTANCE-RELATED DISORDERS; UNITED STATES;

EID: 80054982430     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2011.05.013     Document Type: Article

References (20)

1. Coleman J.J., Schuster C.R., DuPont R.L. Reducing the abuse potential of controlled substances. Pharmaceut. Med. 2010, 24:21-36.
2. The Expert Panel Abuse liability assessment of CNS drugs: conclusions, recommendations, and research priorities. Drug Alcohol Depend. 2003, 70(Suppl. 3):S107-S114.
3. Food and Drug Administration (US) Draft guidance to industry on assessment of abuse potential of drugs. Notice. Fed. Registr. 2010, 75:4400-4401.
4. Food and Drug Administration Amendments Act of 2007, Pub. L. 110-85, 121 Stat. 823 (Sept. 27. 2007).
5. Gold M.S., Merkov M.J. The pharmacology of cocaine, crack and other stimulants. Principles of Addiction Medicine 1998, 137-146. American Society of Addiction Medicine, Chevy Chase, MD. 2nd Ed. A.W. Graham, T.K. Schultz (Eds.).
6. Greely H., Sahakian B., Harris J., Kessler R.C., Gazzaniga M., Campbell P., Farah M.J. Towards responsible use of cognitive-enhancing drugs by the healthy. Nature 2008, 456:702-705.
7. Grudzinkas C., Balster R.L., Gorodetzky C.W., Griffiths R.R., Henningfield J.E., Johanson C., Mansbach R.S., McCormick C.G., Schnoll S.H., Strain E.C., Wright C. Impact of formulation on the abuse liability, safety and regulation of medications: the expert panel report. Drug Alcohol Depend. 2006, 83:S77-S82.
8. Hamburg M.A., Sharfstein J.M. The FDA as a public health agency. N. Engl. J. Med. 2009, 360:2493-2495.
9. Henningfield J.E., Schuster C.R. Risk management and post-marketing of CNS drugs. Drug Alcohol Depend. 2009, 105(Suppl. 1):S56-S64.
10. Johanson C.E., Balster R.L., Henningfield J.E., Schuster C.R., Anthony J.C., Barthwell A.G., Coleman J.J., Dart R.C., Gorodetzky C.W., O'Keeffe C., Sellers E.M., Vocci F., Walsh S.L. Risk management and post-marketing surveillance for the abuse of medications acting on the central nervous system. Drug Alcohol Depend. 2009, 105(Suppl. 1):S65-S71.
11. Kroutil L.A., Van Brunt D.L., Herman-Stahl M.A., Heller D.C., Bray R.M., Penne M.A. Nonmedical use of prescription stimulants in the United States. Drug Alcohol Depend. 2006, 84:135-143.
12. Mansbach R.S., Schoedel K.A., Kittrelle J.P., Sellers E.M. The role of adverse events and safety data in the pre-market evaluation of drug abuse potential. Drug Alcohol Depend. 2010, 112:173-177.
13. Nutt D.J., King L.A., Phillips L.A. Drug harms in the UK: a multicentre decision analysis. Lancet 2010, 376:1558-1565.
14. O'Brien C.P. Drug addiction and drug abuse. Goodman and Gilman's The Pharmacological Basis of Therapeutics 2006, 607-627. McGraw-Hill, New York. 11th Ed. L.L. Brunton, J.S. Lazo, K.L. Parker (Eds.).
15. Office of Applied Studies, 2010. Results from the 2009 National Survey on Drug Use and Health: Volume I. Summary of National Findings. (NSDUH Series H-38A, HHS Publication o. SMA 10-4586). Rockville, MD: Substance Abuse and Mental Health Services Administration.
16. Office of Applied Studies, 2001. National Household Survey on Drug Abuse (NHSDA): Annual Numbers of New Non-medical Users of Prescription Type Drugs, 1965-2000, Summary of National Findings. (NHSDA Series H-17, DHHS Publication No. SMA 02-3758). Rockville, MD: Substance Abuse and Mental Health Services Administration.
17. Potter M., Schafer S., Gonzalez-Mendez E., Gjeltema K., Lopez A., Wu J., Pedrin R., Cozen M., Wilson R., Thom D., Croughan-Minihane M. Opioids for chronic nonmalignant pain. Attitudes and practices of primary care physicians in the UCSF/Stanford Collaborative Research Network. University of California, San Francisco. J. Fam. Pract. 2001, 50:145-151.
18. Rasmussen N. America's first amphetamine epidemic 1929-1971: a quantitative and qualitative retrospective with implications for the present. Am. J. Public Health 2008, 98:974-985. epub April 29, 2008.
19. Schnoll S.H., Ertischek M.D., Henningfield J.E. Risk management programs: a supplement to the Controlled Substances Act. Food Drug Law Regulat. Educ. 2006, 4:19-23.
20. Spillane J., McAllister W.B. Keeping the lid on: a century of regulation and control. Drug Alcohol Depend. 2003, 70(Suppl. 3):S5-S12.